Brolucizimab-leading an era of structural revolution for long-term VEGF suppression

Affiliations

¹ Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, India. drashish79@hotmail.com.
² Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, India.
³ Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
⁴ Department of Ophthalmology, University Vita-Salute Scientific Institute San Raffaele, Milano, Italy.

Ashish Sharma et al. Eye (Lond). 2020 Apr.

. 2020 Apr;34(4):611-613.

doi: 10.1038/s41433-019-0583-z. Epub 2019 Sep 19.

¹ Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, India. drashish79@hotmail.com.
² Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, India.
³ Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
⁴ Department of Ophthalmology, University Vita-Salute Scientific Institute San Raffaele, Milano, Italy.

No abstract available

Conflict of interest statement

The authors declare that they have no conflict of interest.

1. Keane PA, Sadda SR. Development of anti-VEGF therapies for intraocular use: a guide for clinicians. J Ophthalmol. 2012;2012:1–13. - PMC - PubMed
1. Bates A, Power CA. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies. 2019;8:28. - PMC - PubMed
1. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161-6420(18)33018-5. - PubMed
1. Kholodenko RV, Kalinovsky DV, Doronin II, Ponomarev ED, Kholodenko IV. Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations. Curr Med Chem. 2019;26:396–426. - PubMed
1. Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: what’s new? Pharmacol Res. 2016;103:253–69. - PubMed